TY - JOUR
T1 - Stenting and Angioplasty in Neurothrombectomy
T2 - Matched Analysis of Rescue Intracranial Stenting Versus Failed Thrombectomy
AU - Mohammaden, Mahmoud H.
AU - Haussen, Diogo C.
AU - Al-Bayati, Alhamza R.
AU - Hassan, Ameer
AU - Tekle, Wondwossen
AU - Fifi, Johanna
AU - Matsoukas, Stavros
AU - Kuybu, Okkes
AU - Gross, Bradley A.
AU - Lang, Michael J.
AU - Narayanan, Sandra
AU - Cortez, Gustavo M.
AU - Hanel, Ricardo A.
AU - Aghaebrahim, Amin
AU - Sauvageau, Eric
AU - Farooqui, Mudassir
AU - Ortega-Gutierrez, Santiago
AU - Zevallos, Cynthia
AU - Galecio-Castillo, Milagros
AU - Sheth, Sunil A.
AU - Nahhas, Michael
AU - Salazar-Marioni, Sergio
AU - Nguyen, Thanh N.
AU - Abdalkader, Mohamad
AU - Klein, Piers
AU - Hafeez, Muhammad
AU - Kan, Peter
AU - Tanweer, Omar
AU - Khaldi, Ahmad
AU - Li, Hanzhou
AU - Jumaa, Mouhammad
AU - Zaidi, Syed
AU - Oliver, Marion
AU - Salem, Mohamed M.
AU - Burkhardt, Jan Karl
AU - Pukenas, Bryan A.
AU - Alaraj, Ali
AU - Peng, Sophia
AU - Kumar, Rahul
AU - Lai, Michael
AU - Siegler, James
AU - Nogueira, Raul G.
N1 - Funding Information:
Dr Nogueira reports compensation from Anaconda Biomed for consultant services; compensation from Corindus, Inc‚ for consultant services; compensation from Genentech for consultant services; stock options in Brainomix; compensation from Vesalio for consultant services; stock options in Ceretrieve; compensation from Imperative Care for consultant services; compensation from Biogen, Inc‚ for consultant services; stock options in Viz-AI; compensation from Cerenovus for consultant services; compensation from RapidPulse for consultant services; compensation from Medtronic USA, Inc‚ for consultant services; stock options in Vesalio; compensation from Prolong Pharmaceuticals for consultant services; stock options in Corindus, Inc; stock options in Perfuze; compensation from Perfuze for consultant services; compensation from Ceretrieve for consultant services; compensation from Phenox for consultant services; compensation from Brainomix for consultant services; compensation from Stryker Corporation for consultant services; compensation from NeuroVasc Technologies, Inc‚ for consultant services; and compensation from Viz-AI for consultant services. Dr Haussen reports stock options in Viz AI; compensation from Cerenovus for consultant services; compensation from Stryker for consultant services; compensation from Vesalio for consultant services; and compensation from Jacobs institute for data and safety monitoring services. Dr Al-Bayati is a consultant for Stryker Neurovascular. Dr Hassan reports (1) Consultant/speaker: Medtronic, Microvention, Stryker, Penumbra, Cerenovus, Genentech, GE Healthcare, Scientia, Balt, Vizai, Insera therapeutics, Proximie, NovaSignal and Vesalio; (2) Principal investigator: COMPLETE study Penumbra, LVO SYNCHRONISE-Vizai; (3) Steering committee/publication committee member: SELECT, DAWN, SELECT 2, EXPEDITE II, EMBOLISE, CLEAR; (4) Proctor: Pipeline, FRED, Wingspan, and Onyx; and (5) Supported by grants from: GE Healthcare. Dr Nguyen received research support from Medtronic, SVIN. Dr Ortega-Gutierrez reports consulting fees for advisory roles with Stryker Neurovascular, Medtronic and microvention and receives research support from Medtronic, Stryker, Microvention, VizAI. Dr Burkhardt is an Advisory Board Member and consultant for Longeviti Neuro Solutions, and Consultant for Q’Apel Medical. Dr Gross is a consultant for Medtronic and Microvention. Dr Hanel is a consultant for Medtronic, Stryker, Cerenovous, Microvention, Balt, Phenox, Rapid Medical, and Q’Apel, advisory board for MiVI, eLum, Three Rivers, Shape Medical and Corindus. Unrestricted research grant from NIH, Interline Endowment, Microvention, Stryker, CNX. Investor/stockholder for InNeuroCo, Cerebrotech, eLum, Endostream, Three Rivers Medical, Inc, Scientia, RisT, BlinkTBI, and Corindus. Dr Sauvageau reports a speakers’ agreement with Stryker. Dr Aghaebrahim is on advisory board for iSchema View. Dr Siegler reports compensation from Ceribell for consultant services and compensation from AstraZeneca for other services. Dr Alaraj reports compensation from Johnson and Johnson for consultant services. Dr Kan reports compensation from Stryker for consultant services and compensation from MicroVention, Inc‚ for consultant services. Dr Sheth reports employment by UTHealth McGovern Medical School; grants from National Institutes of Health; compensation from Imperative Care, Inc‚ for consultant services; and compensation from Penumbra, Inc‚ for consultant services. Dr Fifi reports compensation from MIVI for data and safety monitoring services; compensation from Stryker Corporation for consultant services; stock holdings in Imperative Care; compensation from MicroVention, Inc‚ for consultant services; compensation from Penumbra, Inc for, consultant services; and compensation from Cerenovus for consultant services. The other authors report no conflicts.
Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - Background: Successful reperfusion is one of the strongest predictors of functional outcomes after mechanical thrombectomy (MT). Despite continuous advancements in MT technology and techniques, reperfusion failure still occurs in ≈15% to 30% of patients with large vessel occlusion strokes undergoing MT. We aim to evaluate the safety and efficacy of rescue intracranial stenting for large vessel occlusion stroke after failed MT. Methods: The SAINT (Stenting and Angioplasty in Neurothrombectomy) Study is a retrospective analysis of prospectively collected data from 14 comprehensive stroke centers through January 2015 to December 2020. Patients were included if they had anterior circulation large vessel occlusion stroke due to intracranial internal carotid artery and middle cerebral artery-M1/M2 segments and failed MT. The cohort was divided into 2 groups: rescue intracranial stenting and failed recanalization (modified Thrombolysis in Cerebral Ischemia score 0-1). Propensity score matching was used to balance the 2 groups. The primary outcome was the shift in the degree of disability as measured by the modified Rankin Scale at 90 days. Secondary outcomes included functional independence (90-day modified Rankin Scale score 0-2). Safety measures included symptomatic intracranial hemorrhage and 90-day mortality. Results: A total of 499 patients were included in the analysis. Compared with the failed reperfusion group, rescue intracranial stenting had a favorable shift in the overall modified Rankin Scale score distribution (acOR, 2.31 [95% CI, 1.61-3.32]; P<0.001), higher rates of functional independence (35.1% versus 7%; adjusted odds ratio [aOR], 6.33 [95% CI, 3.14-12.76]; P<0.001), and lower mortality (28% versus 46.5%; aOR, 0.55 [95% CI, 0.31-0.96]; P=0.04) at 90 days. Rates of symptomatic intracerebral hemorrhage were comparable across both groups (7.1% versus 10.2%; aOR, 0.99 [95% CI, 0.42-2.34]; P=0.98). The matched cohort analysis demonstrated similar results. Specifically, rescue intracranial stenting (n=107) had a favorable shift in the overall modified Rankin Scale score distribution (acOR, 3.74 [95% CI, 2.16-6.57]; P<0.001), higher rates of functional independence (34.6% versus 6.5%; aOR, 10.91 [95% CI, 4.11-28.92]; P<0.001), and lower mortality (29.9% versus 43%; aOR, 0.49 [95% CI, 0.25-0.94]; P=0.03) at 90 days with similar rates of symptomatic intracerebral hemorrhage (7.5% versus 11.2%; aOR, 0.87 [95% CI, 0.31-2.42]; P=0.79) compared with patients who failed to reperfuse (n=107). There was no heterogeneity of treatment effect across the prespecified subgroups for improvement in functional outcomes. Conclusions: Acute intracranial stenting appears to be a safe and effective rescue strategy in patients with large vessel occlusion stroke who failed MT. Randomized multicenter trials are warranted.
AB - Background: Successful reperfusion is one of the strongest predictors of functional outcomes after mechanical thrombectomy (MT). Despite continuous advancements in MT technology and techniques, reperfusion failure still occurs in ≈15% to 30% of patients with large vessel occlusion strokes undergoing MT. We aim to evaluate the safety and efficacy of rescue intracranial stenting for large vessel occlusion stroke after failed MT. Methods: The SAINT (Stenting and Angioplasty in Neurothrombectomy) Study is a retrospective analysis of prospectively collected data from 14 comprehensive stroke centers through January 2015 to December 2020. Patients were included if they had anterior circulation large vessel occlusion stroke due to intracranial internal carotid artery and middle cerebral artery-M1/M2 segments and failed MT. The cohort was divided into 2 groups: rescue intracranial stenting and failed recanalization (modified Thrombolysis in Cerebral Ischemia score 0-1). Propensity score matching was used to balance the 2 groups. The primary outcome was the shift in the degree of disability as measured by the modified Rankin Scale at 90 days. Secondary outcomes included functional independence (90-day modified Rankin Scale score 0-2). Safety measures included symptomatic intracranial hemorrhage and 90-day mortality. Results: A total of 499 patients were included in the analysis. Compared with the failed reperfusion group, rescue intracranial stenting had a favorable shift in the overall modified Rankin Scale score distribution (acOR, 2.31 [95% CI, 1.61-3.32]; P<0.001), higher rates of functional independence (35.1% versus 7%; adjusted odds ratio [aOR], 6.33 [95% CI, 3.14-12.76]; P<0.001), and lower mortality (28% versus 46.5%; aOR, 0.55 [95% CI, 0.31-0.96]; P=0.04) at 90 days. Rates of symptomatic intracerebral hemorrhage were comparable across both groups (7.1% versus 10.2%; aOR, 0.99 [95% CI, 0.42-2.34]; P=0.98). The matched cohort analysis demonstrated similar results. Specifically, rescue intracranial stenting (n=107) had a favorable shift in the overall modified Rankin Scale score distribution (acOR, 3.74 [95% CI, 2.16-6.57]; P<0.001), higher rates of functional independence (34.6% versus 6.5%; aOR, 10.91 [95% CI, 4.11-28.92]; P<0.001), and lower mortality (29.9% versus 43%; aOR, 0.49 [95% CI, 0.25-0.94]; P=0.03) at 90 days with similar rates of symptomatic intracerebral hemorrhage (7.5% versus 11.2%; aOR, 0.87 [95% CI, 0.31-2.42]; P=0.79) compared with patients who failed to reperfuse (n=107). There was no heterogeneity of treatment effect across the prespecified subgroups for improvement in functional outcomes. Conclusions: Acute intracranial stenting appears to be a safe and effective rescue strategy in patients with large vessel occlusion stroke who failed MT. Randomized multicenter trials are warranted.
KW - angioplasty
KW - middle cebrebral artery
KW - reperfusion
KW - rescue
KW - stenting
KW - thrombectomy
UR - http://www.scopus.com/inward/record.url?scp=85136508279&partnerID=8YFLogxK
U2 - 10.1161/STROKEAHA.121.038248
DO - 10.1161/STROKEAHA.121.038248
M3 - Article
C2 - 35770672
AN - SCOPUS:85136508279
VL - 53
SP - 2779
EP - 2788
JO - Stroke
JF - Stroke
SN - 0039-2499
IS - 9
ER -